Novo Nordisk's semaglutide shortage officially concludes in the US, spelling major threat for weight loss drug compounders
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply squeeze on Novo Nordisk’s diabetes and obesity counterpa | The FDA has officially declared an end to the supply squeeze on Novo Nordisk’s GLP-1 drug semaglutide for diabetes and obesity in the U.
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
President Donald Trump and HHS Secretary Robert F. Kennedy Jr. said they will be studying the "threat" to children posed by ...
How can we best treat infectious diseases in people with obesity? Hospital pharmacist and Ph.D. researcher Koen van Rhee ...
One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...
Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.
The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...
A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...
British patients with obesity undergoing hip and knee replacements had less of a need for subsequent revision when, after surgery, they lost weight by using medications such as GLP-1 receptor agonists ...
The Associated Press on MSN8d
Could obesity drugs help with alcohol cravings? New study suggests potentialA new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback